TAK 361S

Drug Profile

TAK 361S

Alternative Names: DTaP/TAK-361S quadruple vaccine - Takeda; Quadruple vaccine including Sabin-IPV - Takeda; Sabin-IPV-containing vaccines - Takeda/Japan Poliomyelitis Research Institute; TAK361S

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 02 Feb 2015 Discontinued - Phase-II for Diphtheria (Combination therapy, Prevention) in Japan (Parenteral)
  • 02 Feb 2015 Discontinued - Phase-II for Pertussis (Combination therapy, Prevention) in Japan (Parenteral)
  • 02 Feb 2015 Discontinued - Phase-II for Poliomyelitis (Combination therapy, Prevention) in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top